CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $9,007,000 | -22.7% | 410,360 | 0.0% | 8.99% | +44.2% |
| Q4 2021 | $11,658,000 | -32.5% | 410,360 | -50.0% | 6.24% | -12.8% |
| Q3 2021 | $17,276,000 | +11.7% | 820,720 | 0.0% | 7.15% | +39.5% |
| Q2 2021 | $15,471,000 | -50.1% | 820,720 | -59.6% | 5.13% | -15.2% |
| Q1 2021 | $31,028,000 | +8.3% | 2,030,616 | 0.0% | 6.04% | +103.2% |
| Q4 2020 | $28,652,000 | -10.0% | 2,030,616 | 0.0% | 2.98% | -48.9% |
| Q3 2020 | $31,820,000 | -99.9% | 2,030,616 | 0.0% | 5.82% | +14.0% |
| Q2 2020 | $35,576,392,000 | – | 2,030,616 | – | 5.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |